Evidence map›Paper›PMID 25657593›Full record

ReviewClinical epidemiology2015

The clinical epidemiology of male osteoporosis: a review of the recent literature.

Tina Willson, Scott D Nelson, Jonathan Newbold, Richard E Nelson, Joanne LaFleur

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical epidemiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Trial
  12. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Trial
  13. Trial
  14. Low-Level Cadmium Exposure Is Associated With Decreased Bone Mineral Density and Increased Risk of Incident Fractures in Elderly Men: The MrOS Sweden Study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016
    Trial
  15. Article
  16. Vertebral bone quality score as a novel tool for bone mineral density assessment: which measurement approach is more accurate?European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  17. Observational
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tina WillsonUniversity of Utah College of Pharmacy, Salt Lake City, UT, USA ; Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Scott D NelsonUniversity of Utah College of Pharmacy, Salt Lake City, UT, USA ; Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Jonathan NewboldUniversity of Utah College of Pharmacy, Salt Lake City, UT, USA.
Richard E NelsonVeterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA ; University of Utah School of Medicine, Salt Lake City, UT, USA.
Joanne LaFleurUniversity of Utah College of Pharmacy, Salt Lake City, UT, USA ; Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis, a musculoskeletal disease characterized by decreased bone mineral density (BMD) and an increased risk of fragility fractures, is now recognized as an important public health problem in men. Osteoporotic fractures, particularly of the hip, result in significant morbidity and mortality in men and lead to considerable societal costs. Many national and international organizations now address screening and treatment for men in their osteoporosis clinical guidelines. However, male osteoporosis remains largely underdiagnosed and undertreated. The objective of this paper is to provide an overview of recent findings in male osteoporosis, including pathophysiology, epidemiology, and incidence and burden of fracture, and discuss current knowledge about the evaluation and treatment of osteoporosis in males. In particular, clinical practice guidelines, fracture risk assessment, and evidence of treatment effectiveness in men are addressed.

Indexed as

diagnosisfracture riskguidelinesscreeningtreatment

Identifiers

PMID25657593
PMCPMC4295898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.